COMP <GO>
AUPH vs MRK // OPERATING MARGIN
Aurinia Pharmaceuticals Inc (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: AUPH 8
— MRK 4
▲ OPERATING MARGIN LEADER: AUPH
LAST: $16.65 (-3.25%) • MKT CAP: $2.29B
operating-margins
37.10%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
operating-margins
34.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AUPH VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AUPH | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 74.80% | +13.70 | AUPH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | 20.70% | -4.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.1x | 15.3x | +5.80 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 5.92% | 3.42% | +2.50 | AUPH | /fcf-yield <GO> |
| Operating Margin ACTIVE | 37.10% | 34.30% | +2.80 | AUPH | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.10% | +39.90 | AUPH | /net-margins <GO> |
| Revenue Growth (YoY) | 20.40% | 1.30% | +19.10 | AUPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.33 | 5.19 | +3.14 | AUPH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 51.7 | +5.60 | AUPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.7x | 18.4x | -11.70 | AUPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.29B | $361.02B | -$358.73B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AUPH REV | MRK REV | AUPH GROSS % | MRK GROSS % | AUPH FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $283.1M | $65.01B | 88.5% | 74.8% | $135.7M | $12.36B |
| FY 2024 | $235.1M | $64.17B | 88.0% | 76.3% | $44.4M | $18.10B |
| FY 2023 | $175.5M | $60.12B | — | — | -$33.5M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AUPH // BETA —
MRK // BETA 0.92